Immunome submits FDA application for varegacestat in desmoid tumors: full analysis

Immunome has moved varegacestat into the regulatory phase, announcing on April 29, 2026, that it submitted an NDA to the US FDA for treatment of adults with desmoid tumors. The candidate is an investigational, oral, once-daily gamma secretase inhibitor, and the submission gives the company a potential near-term commercial asset in a rare tumor setting where treatment options have only recently begun to expand. (biospace.com)

This step had been telegraphed for months. In its March 3, 2026, full-year business update and in its 2025 annual report, Immunome said it planned to file in the second quarter of 2026 after reporting positive topline phase 3 RINGSIDE data in December 2025. The company also disclosed that it had been completing manufacturing, toxicology, and pharmacology work needed to support the application. Immunome acquired varegacestat from Ayala Pharmaceuticals in March 2024, making the NDA submission an important validation point for that transaction and for the company’s effort to build a broader targeted oncology portfolio. (investors.immunome.com)

The core evidence package comes from the global, randomized, double-blind, placebo-controlled phase 3 RINGSIDE study in 156 patients with progressing desmoid tumors. Immunome has reported that varegacestat reduced the risk of progression or death by 84% versus placebo, with a hazard ratio of 0.16 and p<0.0001. The company also said the trial met all key secondary endpoints, including a 56% confirmed objective response rate versus 9% with placebo, statistically significant improvements in landmark tumor volume reduction and worst pain intensity, and an exploratory median best tumor-volume change of -83% versus +11% for placebo. Immunome has described the safety profile as generally manageable and consistent with the gamma secretase inhibitor class. (investors.immunome.com)

The broader backdrop matters here. Desmoid tumors are rare, locally aggressive fibroblastic tumors that do not metastasize, but can still cause major morbidity through pain, reduced mobility, deformity, and damage to nearby structures. Immunome says roughly 1,000 to 1,650 patients are diagnosed each year in the US, and recurrence has historically been a major challenge, especially after surgery. Before the FDA approved nirogacestat in November 2023, systemic options were more fragmented, spanning surveillance, surgery, radiation, chemotherapy, and tyrosine kinase inhibitors. Nirogacestat became the first FDA-approved therapy for adults with progressing desmoid tumors who require systemic treatment, establishing gamma secretase inhibition as a validated mechanism in this disease. (sec.gov)

That existing approval also shapes how the market may read varegacestat’s prospects. Immunome has emphasized once-daily dosing, compared with nirogacestat’s twice-daily schedule, though there has been no head-to-head trial and any advantage on tolerability, adherence, or positioning remains an inference rather than a demonstrated comparative outcome. A recent expert review in Expert Opinion on Pharmacotherapy highlights how gamma secretase inhibitors have changed the treatment landscape in desmoid tumors, with growing attention not just to tumor control, but also to patient-reported outcomes and quality of life. (sec.gov)

Why it matters: For veterinary professionals, this is mainly a translational and market-intelligence story rather than a practice-changing one. Still, it’s a useful example of how regulators and drug developers are evaluating therapies for locally aggressive tumors where metastatic spread is not the central problem, but pain, function, recurrence, and long-term morbidity are. The varegacestat filing underscores the increasing weight of composite clinical value: radiographic control, symptom relief, dosing convenience, and class safety all matter. That framework is relevant well beyond human sarcoma care, especially for clinicians and industry teams watching how targeted agents are being positioned in chronic, difficult-to-manage tumor settings. (sec.gov)

There’s also a business signal in the timing. Immunome has been clear that varegacestat is its lead late-stage asset, and the company has tied the program to broader regulatory, manufacturing, and commercial readiness work. If the FDA accepts the filing, investors and clinicians will start looking for a review classification, a potential PDUFA date, and whether the agency uses any expedited review pathway. No acceptance decision has been announced yet. (investors.immunome.com)

What to watch: The near-term milestones are FDA acceptance of the NDA, any signal on priority versus standard review, and presentation of the full phase 3 RINGSIDE dataset at a major medical meeting, which could give a clearer read on durability, subgroup performance, and safety details beyond the topline results disclosed so far. (sec.gov)